THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 106 filers reported holding THERAVANCE BIOPHARMA INC in Q1 2020. The put-call ratio across all filers is 2.19 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,892,663 | -6.4% | 1,841,560 | +12.3% | 3.92% | -2.2% |
| Q2 2023 | $16,978,720 | +2.2% | 1,640,456 | +7.1% | 4.01% | +22.9% |
| Q1 2023 | $16,611,513 | +2.1% | 1,531,015 | +5.6% | 3.26% | -2.8% |
| Q4 2022 | $16,269,000 | -35.7% | 1,450,000 | -41.9% | 3.36% | -39.6% |
| Q3 2022 | $25,308,000 | +37.1% | 2,495,860 | +22.5% | 5.56% | +58.8% |
| Q2 2022 | $18,463,000 | +40.5% | 2,037,825 | +48.2% | 3.50% | +11.1% |
| Q1 2022 | $13,145,000 | +19.0% | 1,375,000 | +37.5% | 3.15% | +7.3% |
| Q4 2021 | $11,050,000 | +1424.1% | 1,000,000 | +920.9% | 2.93% | +1419.7% |
| Q3 2021 | $725,000 | -83.8% | 97,955 | -43.5% | 0.19% | -53.4% |
| Q4 2019 | $4,487,000 | +261.6% | 173,300 | +172.1% | 0.41% | +253.8% |
| Q3 2019 | $1,241,000 | – | 63,681 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chescapmanager LLC | 1,134,718 | $23,160,000 | 2.47% |
| Baupost Group | 8,735,168 | $178,285,000 | 1.42% |
| Orbimed Advisors | 6,219,110 | $126,932,000 | 1.19% |
| CM Management, LLC | 50,000 | $1,021,000 | 0.76% |
| Tekla Capital Management LLC | 456,296 | $9,313,000 | 0.32% |
| Rock Springs Capital Management LP | 682,600 | $13,932,000 | 0.30% |
| Virtus ETF Advisers LLC | 32,871 | $671,000 | 0.28% |
| Cormorant Asset Management, LP | 550,000 | $11,226,000 | 0.25% |
| DAFNA Capital Management LLC | 41,165 | $840,000 | 0.20% |
| PEREGRINE CAPITAL MANAGEMENT LLC | 484,206 | $9,883,000 | 0.18% |